RxDoctor Payments Data

Stephen Cross, MD

Ophthalmology · Columbia, SCNPI 1063737351

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 29.3% of the total. Reporting peaked in 2022 at $4,087 and has fallen 72.4% since, to $1,127 in 2025.

$11,062in general payments, 2019–2025

Across 202 payments — averaging $54.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$3K
  • Glaukos Corporation$3K
  • Sun Pharmaceutical Industries Inc.$1K
  • Alcon$745
  • AbbVie$525
  • Sight Sciences, Inc.$430
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$5,37549%
  • Speaking & faculty fees$280%
  • Food & beverage$5,65951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,062 in reported general payments places this provider in the 85th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$474,557
Medicare patients
922
Services billed
2,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast58$76,506
RestasisCyclosporine58$56,143
MieboPerfluorohexyloctane/Pf35$27,644
CequaCyclosporine29$26,005
ProlensaBromfenac Sodium71$25,051
Bromfenac Sodium127$24,561
IlevroNepafenac67$24,513
Cyclosporine41$22,704
Prednisolone Acetate419$20,538
TyrvayaVarenicline Tartrate19$12,621
Fluorometholone113$10,330
LumiganBimatoprost18$8,917
CombiganBrimonidine Tartrate/Timolol33$8,010
RocklatanNetarsudil Mesylat/Latanoprost15$6,031
Brimonidine Tartrate229$5,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$328$104,15093 claims
AbbVieRestasis, Lumigan, Combigan$525$73,071109 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$223$28,86094 claims
Sun Pharmaceutical Industries Inc.Cequa$1,009$26,00529 claims
NovartisIlevro$256$24,51367 claims
Oyster Point Pharma, Inc.Tyrvaya$25$12,62119 claims
Aerie Pharmaceuticals, Inc.Rocklatan$20$6,03115 claims
Eyevance Pharmaceuticals LLCFlarex$12$1,80913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →